Antagonist antibodies and drugs for immune inhibitory pathways and agonist antibodies for co-stimulatory receptors in clinical testing for cancer
| Target | Agent | Company | Indication | Stage of Development |
| Inhibitory pathway antagonists | ||||
| CTLA-4 | Ipilimumab (αCTLA-4 Mab) | Bristol-Myers Squibb | Melanoma | FDA approved |
| Multiple cancers | Phase 1–3 | |||
| Tremilimumab (αCTLA-4 Mab) | MedImmune | TBDb | ||
| PD-1/PD-L1 | MDX1106 (αPD-1 Mab) | Bristol-Myers Squibb | Melanoma, lung, kidney, etc. | Phase 1–3 |
| MK3475 (αPD-1 Mab) | Merck | Multiple cancers | Phase 1 | |
| Amp224 (B7-DC-Ig) | Amplimmune/GlaxoSmithKline | Multiple cancers | Phase 1 | |
| CT-011a (αPD-1) | CureTech | Multiple cancers | Phase 1/2 | |
| MDX1105 (αPD-L1 Mab) | Bristol-Myers Squibb | Multiple cancers | Phase 1 | |
| B7-H3 | MGA271 (αB7-H3 Mab) | Macrogenics | Multiple cancers | Phase 1 |
| IDO | D-1-methyl tryptophan | NewLink | Multiple cancers | Phase 1/2 |
| Co-stimulatory pathway agonists | ||||
| CD137 | BMS663513 (αCD137 Mab) | Bristol-Myers Squibb | TBDb | |
| CD40 | CP-870893 (αCD40 Mab) | Pfizer | Pancreas cancer | Phase 1 |
| OX40 | Anti-OX40 Mab | AgonOX | Multiple cancers | Phase 1/2 |
| CD127 | CDX-1127 (αCD27 Mab) | Celldex | Multiple cancers | Phase 1 |
| Target | Agent | Company | Indication | Stage of Development |
| Inhibitory pathway antagonists | ||||
| CTLA-4 | Ipilimumab (αCTLA-4 Mab) | Bristol-Myers Squibb | Melanoma | FDA approved |
| Multiple cancers | Phase 1–3 | |||
| Tremilimumab (αCTLA-4 Mab) | MedImmune | TBDb | ||
| PD-1/PD-L1 | MDX1106 (αPD-1 Mab) | Bristol-Myers Squibb | Melanoma, lung, kidney, etc. | Phase 1–3 |
| MK3475 (αPD-1 Mab) | Merck | Multiple cancers | Phase 1 | |
| Amp224 (B7-DC-Ig) | Amplimmune/GlaxoSmithKline | Multiple cancers | Phase 1 | |
| CT-011a (αPD-1) | CureTech | Multiple cancers | Phase 1/2 | |
| MDX1105 (αPD-L1 Mab) | Bristol-Myers Squibb | Multiple cancers | Phase 1 | |
| B7-H3 | MGA271 (αB7-H3 Mab) | Macrogenics | Multiple cancers | Phase 1 |
| IDO | D-1-methyl tryptophan | NewLink | Multiple cancers | Phase 1/2 |
| Co-stimulatory pathway agonists | ||||
| CD137 | BMS663513 (αCD137 Mab) | Bristol-Myers Squibb | TBDb | |
| CD40 | CP-870893 (αCD40 Mab) | Pfizer | Pancreas cancer | Phase 1 |
| OX40 | Anti-OX40 Mab | AgonOX | Multiple cancers | Phase 1/2 |
| CD127 | CDX-1127 (αCD27 Mab) | Celldex | Multiple cancers | Phase 1 |